Genomic characterization of response to chemoradiation in urothelial bladder cancer

The authors characterized the genetic landscape of chemoradiation‐treated urothelial carcinoma of the bladder (UCB) with the objective of identifying potential correlates of response.

[1]  Roland L Dunbrack,et al.  Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. , 2015, European urology.

[2]  N. Socci,et al.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.

[3]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[4]  N. Schultz,et al.  Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. , 2015, European urology.

[5]  R. Mak,et al.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Yusuke Nakamura,et al.  Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival , 2014, Clinical Cancer Research.

[7]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[8]  Nicholas D James,et al.  Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. , 2014, European urology.

[9]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[10]  K. Manova-Todorova,et al.  The Mre11 complex suppresses oncogene-driven breast tumorigenesis and metastasis. , 2013, Molecular cell.

[11]  M. Berger,et al.  Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. , 2013, Journal of visualized experiments : JoVE.

[12]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[13]  Arndt Hartmann,et al.  Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer , 2012, BJU international.

[14]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[15]  L. Thompson.  Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. , 2012, Mutation research.

[16]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[17]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[18]  Ananya Choudhury,et al.  MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. , 2010, Cancer research.

[19]  P. Hanawalt,et al.  Transcription-coupled DNA repair: two decades of progress and surprises , 2008, Nature Reviews Molecular Cell Biology.

[20]  John D. Roberts,et al.  RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. , 2003, International journal of radiation oncology, biology, physics.

[21]  H. Sandler,et al.  Overview of bladder cancer trials in the Radiation Therapy Oncology Group , 2003, Cancer.

[22]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Lawton.  Bladder-sparing, Combined-modality Approach for Muscle-invasive Bladder Cancer: A Multi-institutional, Long-term Experience , 2009 .

[24]  R. Autorino,et al.  Bladder‐sparing, combined‐modality approach for muscle‐invasive bladder cancer , 2008, Cancer.

[25]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..